CPBIO Holding Company Limited (HKG:3839)

Hong Kong · Delayed Price · Currency is HKD

7.92

-0.02 (-0.25%)

Oct 9, 2026, 3:56 PM HKT

Market Cap	2.01B -6.8%
Revenue (ttm)	3.32B -18.9%
Net Income	191.60M -6.9%
EPS	0.76 -6.9%
Shares Out	253.33M
PE Ratio	10.47
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,100
Open	7.94
Previous Close	7.94
Day's Range	7.91 - 7.94
52-Week Range	5.50 - 9.89
Beta	3.99
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 10, 2026

About CPBIO Holding Company

CPBIO Holding Company Limited manufactures and sells animal health products and chlortetracycline in Mainland China, the Asia Pacific, the Americas, Europe, and internationally. It operates through two segments: Biotech Business and Investment Business. The Biochemical segment is engaged in the manufacture and/or sale of animal health products and chlortetracycline, which are used as feed additives to promote growth of livestock, prevent or cure animal diseases, and enhance efficiency under the Shihao and Citifac brand names. The company offers... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1987

Employees 1,000

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 3839

Full Company Profile

Financial Performance

In 2025, CPBIO Holding Company's revenue was $535.91 million, an increase of 74.14% compared to the previous year's $307.75 million. Earnings were $32.06 million, an increase of 187.03%.

Financial numbers in USD Financial Statements